Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PMB-104
- Development stage
- Unknown
- Lead developer
- Protheragen
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Parenteral
01
Overview
PMB-104 is a monoclonal antibody developed by Protheragen for the treatment of asthma. It specifically targets Immunoglobulin E (IgE), a key mediator in the allergic cascade. By binding to circulating IgE, PMB-104 prevents the interaction between IgE and its high-affinity receptor (FcεRI) on the surface of mast cells and basophils. This blockade inhibits the release of histamine, leukotrienes, and other pro-inflammatory cytokines, thereby reducing airway inflammation and hyperresponsiveness. The drug is currently in Phase I clinical development and is positioned as a targeted biologic therapy for allergic respiratory conditions.
02
Targets
IgE (Immunoglobulin E)
Beyond the preview
Go deeper on PMB-104.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PMB-104.